BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678

 Key Statistics

Ownership: Public

Web Site: OncoGenex Pharmaceuticals Inc.
Symbol: OGXI

 Company News
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Data To Be Presented At ASCO 2015 Annual Meeting 5/20/2015 10:53:17 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For First Quarter 2015 5/14/2015 3:14:19 PM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report First Quarter 2015 Financial Results On May 14, 2015 5/4/2015 2:09:51 PM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC 4/30/2015 6:46:43 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015 6:19:57 AM
Teva (TEVA) Pays $23.2 Million to Dump OncoGenex Pharmaceuticals Inc. (OGXI) Drug 4/27/2015 6:08:25 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Present At The 14th Annual Needham Healthcare Conference 4/9/2015 7:47:16 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Fourth Quarter And Year End 2014 3/27/2015 7:45:07 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015 3/23/2015 8:58:10 AM
OncoGenex Pharmaceuticals Inc. (OGXI) And Sarah Cannon Research Institute Announce Completion Of Patient Enrollment In The Spruce Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 2/24/2015 7:51:52 AM